POINT Biopharma Global Inc., operating under the SPAC ticker RACA, submitted a Form 10-Q to the Securities and Exchange Commission on November 2, 2020, during the vehicle's active pre-combination phase. Focused on the biopharmaceutical sector — specifically the development and commercialization of radioligand therapies targeting oncology indications — the company represented one of the healthcare-oriented SPAC vehicles active during a period of elevated blank-check issuance across U.S. markets. The quarterly filing documented the entity's financial condition and material operational disclosures as it progressed through its SPAC lifecycle. Sign up at SpacDesk for complete filing history, sponsor profiles, and deal analytics on RACA and the full SPAC universe.